Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...
Hoth Therapeutics Inc. has released preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).
Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...
Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...
RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...
The study demonstrated a considerable reduction in tumor growth and KIT protein expression, which is often associated with GIST progression. The preclinical data showed that HT-KIT could induce ...
GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback